The Advanced Research Projects Agency for Health (ARPA‑H) awarded funding to seven teams to advance in‑vivo therapies designed to program immune cells and other cell types directly inside the body. Supported modalities include gene editing, mRNA delivery and novel LNP platforms aimed at teaching immune cells to fight disease without ex vivo manufacturing. ARPA‑H’s investment signals sustained government support for translational work that could lower cost and complexity of cell therapies. The awards prioritize scalable, manufacturable delivery solutions and in‑patient editing safety. Recipients will focus on preclinical development and validation, and the program is positioned to feed industry pipelines and public‑private partnerships that aim to bring next‑generation in‑vivo modalities into clinical testing.